Abbott Laboratories (ABT) Equity Average (2009 - 2026)

Abbott Laboratories has disclosed Equity Average across 18 years of filings, most recently posting $52.4 billion for Q1 2026.

• Equity Average for Q1 2026 came in at $52.4 billion, up 118.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $52.4 billion (up 118.74% YoY), and the FY2025 annual result was $26.5 billion, up 21007.97% from the prior year.
• Equity Average came in at $52.4 billion for Q1 2026 at Abbott Laboratories, up from $52.0 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $52.4 billion in Q1 2026 to a low of -$11.6 billion in Q3 2022.
• The 5-year median for Equity Average is $5.1 billion (2022), against an average of $13.8 billion.
• Across the five-year window, Equity Average slumped 363.92% in 2022 and surged 75453.79% in 2025, its largest moves.
• Abbott Laboratories' Equity Average stood at $5.1 billion in 2022, then sank by 183.11% to -$4.2 billion in 2023, then surged by 102.2% to $93.0 million in 2024, then soared by 55832.8% to $52.0 billion in 2025, then climbed by 0.77% to $52.4 billion in 2026.
• The last three Equity Average figures came in at $52.4 billion (Q1 2026), $52.0 billion (Q4 2025), and $49.9 billion (Q3 2025), per Business Quant data.